A Man's Health Took a Dramatic Turn After a Mountain Bike Crash - Here's What Happened
In June 2020, when Andy Provencher crashed his mountain bike and tumbled over the handlebars, he never expected it would change his life forever. The father of three had several broken bones, a punctured lung, and doctors' worst fears - cancer.
The emergency room doctor told him that scans revealed masses in his lungs, indicative of a very aggressive form of lung cancer. Provencher was shocked and devastated, thinking this was the end for him. However, as the years went by, he faced numerous challenges in getting an accurate diagnosis.
"I went to every doctor there was," Provencher said. "I saw my primary care physician, a hematologist, a pulmonologist, a rheumatologist, but we never had a solid answer or a solid diagnosis."
Meanwhile, Provencher's condition worsened, and he lost energy, struggled to walk up stairs, and endured excruciating pain, making him move like an 90-year-old man. He was advised to start chemotherapy, but it wasn't the right treatment for his mysterious illness.
Two weeks before starting the aggressive treatment, Provencher met a physician assistant who specialized in rheumatology. They discovered that Provencher had IgG4-RD, a rare immune disorder that can affect virtually any organ system. The diagnosis came as a surprise, and it changed everything.
"IgG4-RD moves slowly," said Dr. Ambreesh Chawla, a rheumatologist at the Cleveland Clinic. "It often damages organs before patients even know something is wrong." The condition has no permanent cure but can be managed with treatment.
Provencher was enrolled in a clinical trial to test the efficacy of inebilizumab, a medication that targets CD19, an antigen found only on the surface of B cells. The results were astonishing - 87% of patients who received inebilizumab saw their risk of disease flare reduced over one year.
In April 2025, inebilizumab became the first FDA-approved treatment for IgG4-RD. Three years after his diagnosis, Provencher is still taking the medication and feeling great. He has the energy to play with his kids and go out with friends.
While there's no permanent cure for IgG4-RD, Provencher hopes that further advocacy and education about the disease can lead to a better diagnostic process. "The most important thing is just keep going," he said. "Keep asking questions, keep moving forward."
In June 2020, when Andy Provencher crashed his mountain bike and tumbled over the handlebars, he never expected it would change his life forever. The father of three had several broken bones, a punctured lung, and doctors' worst fears - cancer.
The emergency room doctor told him that scans revealed masses in his lungs, indicative of a very aggressive form of lung cancer. Provencher was shocked and devastated, thinking this was the end for him. However, as the years went by, he faced numerous challenges in getting an accurate diagnosis.
"I went to every doctor there was," Provencher said. "I saw my primary care physician, a hematologist, a pulmonologist, a rheumatologist, but we never had a solid answer or a solid diagnosis."
Meanwhile, Provencher's condition worsened, and he lost energy, struggled to walk up stairs, and endured excruciating pain, making him move like an 90-year-old man. He was advised to start chemotherapy, but it wasn't the right treatment for his mysterious illness.
Two weeks before starting the aggressive treatment, Provencher met a physician assistant who specialized in rheumatology. They discovered that Provencher had IgG4-RD, a rare immune disorder that can affect virtually any organ system. The diagnosis came as a surprise, and it changed everything.
"IgG4-RD moves slowly," said Dr. Ambreesh Chawla, a rheumatologist at the Cleveland Clinic. "It often damages organs before patients even know something is wrong." The condition has no permanent cure but can be managed with treatment.
Provencher was enrolled in a clinical trial to test the efficacy of inebilizumab, a medication that targets CD19, an antigen found only on the surface of B cells. The results were astonishing - 87% of patients who received inebilizumab saw their risk of disease flare reduced over one year.
In April 2025, inebilizumab became the first FDA-approved treatment for IgG4-RD. Three years after his diagnosis, Provencher is still taking the medication and feeling great. He has the energy to play with his kids and go out with friends.
While there's no permanent cure for IgG4-RD, Provencher hopes that further advocacy and education about the disease can lead to a better diagnostic process. "The most important thing is just keep going," he said. "Keep asking questions, keep moving forward."